Department of Ophthalmology, The Second Hospital of Jilin University, Changchun, China.
Front Immunol. 2019 Mar 29;10:665. doi: 10.3389/fimmu.2019.00665. eCollection 2019.
Behcet's disease (BD) is a chronic systemic inflammatory vasculitis of unknown etiology characterized by recurrent episodes of oral aphthous ulcers, genital ulcers, skin lesions, ocular lesions, and other manifestations. Although the pathogenesis of BD is unclear, some studies have shown that immunological aberrations play an important role in the development and progression of BD. Infection-related trigger factors, including antigens and autoantigens, are believed to mediate the development of BD in patients with a genetic predisposition and subsequently activate the innate and adaptive immune systems, resulting in the production of numerous cytokines and chemokines to combat the infection-related factors. The study of the immunological mechanism of BD paves the way for the development of innovative therapies. Recently, novel biotherapy approaches, including interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) antagonists, and other agents that target interleukins and their receptors, have shown promising results in the treatment of patients with refractory BD and have improved the prognosis of BD. In this review, we provide the current concepts of BD immunopathogenesis.
贝赫切特病(BD)是一种病因不明的慢性系统性炎症性血管炎,其特征是反复发作的口腔阿弗他溃疡、生殖器溃疡、皮肤损害、眼部损害和其他表现。尽管 BD 的发病机制尚不清楚,但一些研究表明,免疫异常在 BD 的发生和发展中起重要作用。感染相关的触发因素,包括抗原和自身抗原,被认为在具有遗传易感性的患者中介导 BD 的发生,并随后激活先天和适应性免疫系统,导致产生大量细胞因子和趋化因子来对抗感染相关因素。对 BD 的免疫机制的研究为开发创新疗法铺平了道路。最近,新型生物疗法方法,包括干扰素-α(IFN-α)、肿瘤坏死因子-α(TNF-α)拮抗剂和其他针对白细胞介素及其受体的药物,在治疗难治性 BD 患者方面显示出有希望的结果,并改善了 BD 的预后。在这篇综述中,我们提供了 BD 免疫发病机制的最新概念。